# Doravirine/Islatravir (DOR/ISL) in Heavily Treatment-Experienced (HTE) Participants for Human Immunodeficiency Virus Type 1 (HIV-1) Infection (MK-8591A-019)

> **NCT04233216** · PHASE3 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 35 (actual)

## Conditions studied

- HIV-1 Infection

## Interventions

- **DRUG:** ISL
- **DRUG:** DOR
- **DRUG:** DOR/ISL
- **DRUG:** Placebo to ISL
- **DRUG:** Placebo to DOR

## Key facts

- **NCT ID:** NCT04233216
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-03-18
- **Primary completion:** 2022-11-21
- **Final completion:** 2023-11-01
- **Target enrollment:** 35 (ACTUAL)
- **Last updated:** 2024-12-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04233216

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04233216, "Doravirine/Islatravir (DOR/ISL) in Heavily Treatment-Experienced (HTE) Participants for Human Immunodeficiency Virus Type 1 (HIV-1) Infection (MK-8591A-019)". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT04233216. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*